Download MendeleyAffinity- and epitope-dependent pathogenicity of GM-CSF autoantibodies in patients with autoimmune pulmonary alveolar proteinosis.
Futami, S., Kawai, C., Kishikawa, J.I., Hirose, M., Kida, H., Wang, P.H., Yamashita, K., Ishikawa, F., Kato, T., Inoue, Y., Kumanogoh, A., Kurosaki, T., Inoue, T.(2026) Nat Commun 17
- PubMed: 42362542 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41467-026-74717-2
- Primary Citation Related Structures:
9JKR - PubMed Abstract:
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease caused by autoantibodies targeting granulocyte-macrophage colony-stimulating factor (GM-CSF). Although serum GM-CSF autoantibody levels are markedly increased in aPAP patients, total antibody titer does not correlate with disease severity. Here, we characterize 186 monoclonal anti-GM-CSF autoantibodies derived from GM-CSF-specific B cells in 28 aPAP patients with varying disease severity, including three longitudinal cohorts, to determine whether epitope specificity and affinity of the autoantibodies contribute to disease pathophysiology. We classify these antibodies into two groups based on their epitopes: class 1 (targeting A, BD, or D epitopes) and class 2 (targeting B or C epitopes). In class 1 antibodies, affinity strongly correlates with neutralization activity, whereas this relationship is weak or absent in class 2 antibodies. High-affinity class 1 antibodies are present at higher levels in patients with more severe disease and are sufficient to induce PAP symptoms in a humanized mouse model. Thus, these findings identify epitope specificity and affinity as key determinants of pathogenicity and provide a mechanistic framework for understanding why total serum autoantibody levels fail to reflect disease severity in aPAP.
- Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, The University of Osaka, Osaka, Japan.
Organizational Affiliation:
